Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260072 · ClinicalTrials.gov registry record · Phase 2
Magnesium and Riboflavin Treatment for Post-Concussion Headache
A Phase 2 study of Concussion, Intermediate, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06260072: Recruiting Phase 2 study of Concussion, Intermediate, sponsored by University of Virginia.
NCT06260072 is a Phase 2 study of Concussion, Intermediate that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 108 participants, below the 247-participant average among 5 other Concussion, Intermediate trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06260072, a Phase 2 study of Concussion, Intermediate, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.
Primary Outcome
t-test of mean differences between the groups
Conditions Studied
Interventions
- DRUG magnesium and riboflavin supplement
Study Locations (1)
Virginia
- University of Virginia Student Health and Wellness Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT06260072 shows while recruiting
NCT06260072 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 247-participant average among 5 other Concussion, Intermediate trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Concussion, Intermediate appearing as the primary indexed condition, and to 1 intervention - of which magnesium and riboflavin supplement is the first listed.
NCT06260072 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06260072 about?
NCT06260072 is a clinical study titled "Magnesium and Riboflavin Treatment for Post-Concussion Headache". This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules...
What is the current status of trial NCT06260072?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2020-02-10. Estimated completion is 2025-12-31.
What conditions does trial NCT06260072 study?
This clinical trial studies the following conditions: Concussion, Intermediate.
What interventions are being tested in trial NCT06260072?
The interventions under investigation include: magnesium and riboflavin supplement (DRUG).
Who is sponsoring clinical trial NCT06260072?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260072 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Concussion, Intermediate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Facilitating Access to Specialty Treatment
RECRUITING · NA
-
Intervention to Change Affect Recognition and Empathy
ACTIVE NOT RECRUITING · NA
-
Unblinded Data Collection Study of Concussion Using BrainPulse
COMPLETED
-
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
COMPLETED
-
Objective Brain Function Assessment of mTBI/Concussion
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI